Finlande occidentale And NotHans Helenius
List of bibliographic references
Number of relevant bibliographic references: 46.Ident. | Authors (with country if any) | Title |
---|---|---|
000128 | M. S. Lee [Corée du Sud] ; C. H. Lyoo [Corée du Sud] ; Y. H. Ryu [Corée du Sud] ; H. S. Lim [Corée du Sud] ; C. M. Nam [Corée du Sud] ; H. S. Kim [Corée du Sud] ; J. O. Rinne [Finlande] | The effect of age on motor deficits and cerebral glucose metabolism of Parkinson’s disease |
000722 | M. Soilu-H Nninen ; E. Broberg ; M. Röytt ; P. Mattila ; J. Rinne [Finlande] ; V. Hukkanen [Finlande] | Expression of LIF and LIF receptor beta in Alzheimer’s and Parkinson’s diseases |
000B04 | H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
000B79 | Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande] | A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen |
000C00 | C. H. Lyoo [Finlande] ; Y. Jeong [Finlande] ; Y. H. Ryu [Finlande] ; S. Y. Lee [Finlande] ; T. J. Song [Finlande] ; J. H. Lee [Finlande] ; J. O. Rinne [Finlande] ; M. S. Lee [Finlande] | Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy |
000D88 | Aki S. Havulinna [Finlande] ; Pentti J. Tienari [Finlande] ; Reijo J. Marttila [Finlande] ; Kirsti K. Martikainen [Finlande] ; Johan G. Eriksson [Finlande] ; Olli Taskinen [Finlande] ; Elena Moltchanova [Finlande] ; Marjatta Karvonen [Finlande] | Geographical variation of medicated parkinsonism in Finland during 1995 to 2000 |
001074 | Chul Hyoung Lyoo [Corée du Sud] ; Sargo Aalto [Finlande] ; Juha O. Rinne [Finlande] ; Ki Ook Lee [Corée du Sud] ; Seung Hun Oh [Corée du Sud] ; Jin Woo Chang [Corée du Sud] ; Myung Sik Lee [Corée du Sud] | Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait |
001241 | Kirsti K. Martikainen [Finlande] ; Tiina H. Luukkaala [Finlande] ; Reijo J. Marttila [Finlande] | Parkinson's disease and working capacity |
001720 | Elina Nurmi [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande] ; Tero Vahlberg [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande] | Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET |
001758 | N. Kemppainen [Finlande] ; M. Laine [Finlande] ; M. P. Laakso [Finlande] ; V. Kaasinen [Finlande] ; K. N Gren [Finlande] ; T. Vahlberg [Finlande] ; T. Kurki [Finlande] ; J. O. Rinne [Finlande] | Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease |
001990 | Juha O. Rinne [Finlande] ; Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Olli Eskola [Finlande] ; Olof Solin [Finlande] | [18F]FDOPA and [18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease |
001A22 | Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande] | Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study |
001A31 | Anna Brück [Finlande] ; Raija Portin [Finlande] ; Arja Lindell [Finlande] ; Arto Laihinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Juha O. Rinne [Finlande] | Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus |
001A85 | Hanna M. Ruottinen [Finlande] ; Mikko Niinivirta [Finlande] ; Jörgen Bergman [Finlande] ; Vesa Oikonen [Finlande] ; Olof Solin [Finlande] ; Olli Eskola [Finlande] ; Esa Eronen [Finlande] ; Pirkko Sonninen [Finlande] ; Urpo K. Rinne [Finlande] | Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging |
001C61 | Oleg V. Anichtchik [Finlande] ; Juha O. Rinne [Finlande] ; Hannu Kalimo [Finlande] ; Pertti Panula [Finlande] | An Altered Histaminergic Innervation of the Substantia Nigra in Parkinson's Disease |
001D39 | H. Przuntek ; B. Conrad [Allemagne] ; J. Dichgans ; P. H. Kraus ; P. Krauseneck ; G. Pergande ; U. Rinne [Finlande] ; K. Schimrigk ; J. Schnitker ; H. P. Vogel [Allemagne] | SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa |
001F63 | Shuang Yong Ma [Finlande] ; Matias Röytt [Finlande] ; Juha O. Rinne [Finlande] ; Yrjö Collan [Finlande] ; Urpo K. Rinne [Finlande] | Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts |
001F92 | V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande] | Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study |
002115 | Shuang Yong Ma [Finlande] ; Juha O. Rinne [Finlande] ; Yrjö Collan [Finlande] ; Matias Röytt [Finlande] ; Urpo K. Rinne [Finlande] | A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease |
002224 | Juha O. Rinne [Finlande] ; Jyrki T. Kuikka [Finlande] ; Kim A. Bergström [Finlande] ; Urpo K. Rinne [Finlande] | Striatal dopamine transporter in different disability stages of Parkinson's disease studied with [123I]β-CIT SPECT |
002247 | Juha O. Rinne [Finlande] ; Arto Laihinen [Finlande] ; Hanna Ruottinen [Finlande] ; Ulla Ruotsalainen [Finlande] ; Kjell N Gren [Finlande] ; Pertti Lehikoinen [Finlande] ; Vesa Oikonen [Finlande] ; U. K. Rinne [Finlande] | Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride |
002300 | Juha O. Rinne [Finlande] ; Arto Laihinen [Finlande] ; Kjell N Gren [Finlande] ; Hanna Ruottinen [Finlande] ; Ulla Ruotsawnen [Finlande] ; Urpo K. Rinne [Finlande] | PET examination of the monoamine transporter with [11c]β‐CIT and [11c]β‐CFT in early parkinson's disease |
002528 | Rinne [Finlande] | Nigral degeneration in parkinson's disease |
002549 | H. Heinonen [Finlande] ; M. Savij Rvi [Finlande] ; M. Kotila [Finlande] ; A. Hajba [Finlande] ; M. Scheinin [Finlande] | Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease |
002686 | R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] ; R. J. Marttila [Finlande] | Progression and survival in Parkinson's disease |
002692 | J. O. Rinne [Finlande] | Nigral degeneration in Parkinson's disease in relation to clinical features |
002693 | U. K. Rinne [Finlande] | New strategies in the treatment of early Parkinson's disease |
002725 | E. H. Heinonen [Finlande] ; R. Lammintausta [Finlande] | A review of the pharmacology of selegiline |
002823 | Heinonen E. H [Finlande] ; Rinne U. K [Finlande] | Selegiline in the treatment of Parkinson's disease |
002826 | Heinonen E. H [Finlande] ; Myllyl V ; Sotaniemi K ; Lammintausta R [Finlande] ; Salonen J. S [Finlande] ; Anttila M [Finlande] ; Savij Rvi M ; Kotila M ; Rinne U. K [Finlande] | Pharmacokinetics and metabolism of selegiline |
002836 | R. J. Marttila [Finlande] ; U. K. Rinne [Finlande] | Epidemiological approaches to the etiology of Parkinson's disease |
002919 | A. Laihinen [Finlande] ; J. Alihanka [Finlande] ; S. Raitasuo [Finlande] ; U. K. Rinne [Finlande] | Sleep movements and associated autonomic nervous activities in patients with Parkinson's disease |
002A80 | U. K. Rinne [Finlande] | Problems associated with long‐term levodopa treatment of Parkinson's disease |
002A89 | Reijo J. Marttila [Finlande] | Diagnosis and epidemiology of Parkinson's disease |
002B00 | Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] ; Anja Tiilikainen | Virus antibodies in Parkinson's disease |
002B38 | K. Rinne [Finlande] | Treatment of Parkinson's disease: Problems with a progressing disease |
002B50 | J. Marttila [Finlande] ; K. Rinne [Finlande] | Epidemiology of Parkinson's disease—An overview |
002B51 | K. Rinne [Finlande] ; P. Lönnberg [Finlande] ; V. Koskinen [Finlande] | Dopamine receptors in the parkinsonian brain |
002B91 | Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | Changing epidemiology of Parkinson's disease: Predicted effects of levodopa treatment |
002C12 | Rinne [Finlande] ; R. Marttila [Finlande] | Brain dopamine receptor stimulation and the relief of parkinsonism: Relationship between bromocriptine and levodopa |
002C27 | J. Marttila [Finlande] ; K. Rinne [Finlande] ; T. Siirtola [Finlande] ; V. Sonninen [Finlande] | Mortality of patients with parkinson's disease treated with levodopa |
002C31 | Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | DISABILITY AND PROGRESSION IN PARKINSON'S DISEASE |
002C47 | Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | DEMENTIA IN PARKINSON'S DISEASE |
002C48 | R. J. Marttila ; U. K. Rinne [Finlande] | Arteriosclerosis, heredity, and some previous infections in the etiology of parkinson's disease. A case-control study |
002C58 | K. Rinne [Finlande] ; E. Birket-Smith [Danemark] ; E. Dupont [Danemark] ; E. Hansen [Danemark] ; M. Hyypp [Finlande] ; R. Marttila [Finlande] ; B. Mikkelsen [Danemark] ; H. Pakkenberg [Danemark] ; J. Presthus [Norvège] | Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (madopar®) in the treatment of Parkinson's disease |
002C94 | K. Rinne [Finlande] ; V. Sonninen [Finlande] ; T. Siirtola [Finlande] | Treatment of Parkinson's disease with l -DOPA and decarboxylase inhibitor |
![]() | This area was generated with Dilib version V0.6.23. | ![]() |